Immuneering (NASDAQ:IMRX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Immuneering (NASDAQ:IMRX) from a sell rating to a hold rating in a research report report published on Sunday.

Other equities research analysts have also recently issued research reports about the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immuneering in a report on Friday, March 27th. Needham & Company LLC reissued a “buy” rating and issued a $11.00 price objective on shares of Immuneering in a report on Monday, March 9th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $16.50.

Immuneering Stock Performance

Immuneering stock opened at $5.55 on Friday. The company has a 50-day simple moving average of $5.23 and a 200-day simple moving average of $5.76. The firm has a market capitalization of $358.82 million, a P/E ratio of -4.02 and a beta of 0.43. Immuneering has a one year low of $1.10 and a one year high of $10.08.

Immuneering (NASDAQ:IMRX) last issued its quarterly earnings data on Friday, March 6th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.13. As a group, sell-side analysts forecast that Immuneering will post -1.42 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Sanofi bought a new stake in Immuneering in the third quarter worth about $18,960,000. Empery Asset Management LP acquired a new stake in Immuneering in the 4th quarter valued at about $17,601,000. Vanguard Group Inc. boosted its position in shares of Immuneering by 128.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,415,244 shares of the company’s stock valued at $16,907,000 after purchasing an additional 1,358,322 shares in the last quarter. State Street Corp boosted its position in shares of Immuneering by 1,289.7% during the 4th quarter. State Street Corp now owns 2,402,238 shares of the company’s stock valued at $15,807,000 after purchasing an additional 2,229,374 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its stake in shares of Immuneering by 10.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,993,958 shares of the company’s stock worth $13,121,000 after purchasing an additional 195,176 shares during the last quarter. Institutional investors own 67.65% of the company’s stock.

Immuneering Company Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.